idarubicin has been researched along with Hematologic Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A | 1 |
| Bonkovsky, HL; D'Agostino, RB; Hundley, WG; Jordan, JH; Lamar, ZS; Meléndez, GC; Poole, LB; Porosnicu, M; Vera, T; Whitlock, MC | 1 |
| Blijlevens, NM; Buurman, WA; Derikx, JP; Donnelly, JP; Fujii, H; Heineman, E; Kanda, T; van Bijnen, AA | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Fang, J; Hong, M; Hu, C; Hu, Y; Wu, Q; Xia, L; You, Y; Zhong, Z; Zou, P | 1 |
| Blijlevens, NM; de Pauw, BE; Donnelly, JP | 1 |
| Barbui, T; Bassan, R; Chiodini, B; Cornelli, PE; Cortelazzo, S; Lerede, T; Zucchetti, M | 1 |
| Arcese, W; Cimino, G; De Felice, L; Girelli, G; Girmenia, C; Gozzer, M; Guglielmi, C; Iori, AP; Mandelli, F; Mengarelli, A; Perrone, MP; Ricci, R; Testi, AM | 1 |
1 trial(s) available for idarubicin and Hematologic Neoplasms
| Article | Year |
|---|---|
Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematologic Neoplasms; Humans; Idarubicin; Lymphoproliferative Disorders; Male; Middle Aged | 1998 |
7 other study(ies) available for idarubicin and Hematologic Neoplasms
| Article | Year |
|---|---|
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia | 2020 |
Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bilirubin; Breast Neoplasms; Daunorubicin; Doxorubicin; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Middle Aged; Oxidative Stress; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left | 2015 |
Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients.
Topics: Adult; Aged; Antineoplastic Agents; Carrier Proteins; Citrulline; Cohort Studies; Cyclophosphamide; Enterocytes; Enzyme-Linked Immunosorbent Assay; Fatty Acid-Binding Proteins; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intestinal Mucosa; Longitudinal Studies; Male; Membrane Glycoproteins; Middle Aged; Molecular Weight; Mucositis; Reference Standards; Time Factors; Transplantation Conditioning; Whole-Body Irradiation | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chimerism; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2012 |
Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intestinal Mucosa; Lactulose; Male; Middle Aged; Myeloablative Agonists; Permeability; Prospective Studies; Rhamnose; Stomatitis; Transplantation Conditioning | 2005 |
Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Middle Aged; Transplantation, Homologous; Treatment Outcome | 2000 |